Immuron Limited · ASX:IMC
Immuron — Shareholder Meeting (November 2024)
19 slides from Immuron's shareholder meeting presentation, Nov 18, 2024
Slide 1: Immuron 2024 AGM Presentation
a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce Immuron 2024 AGM Presentation Highlights: ● Global sales increased 172% in FY24 to $4.90m; Record Travelan ® sales of $4.86m ● Record monthly sales in October 2024 of $1.49m ● Completed and reported
Slide 2: © Immuren
© Immuren
Slide 3: Travelers' diarrhea and Immuron platform technology
Travelers’ diarrhea (TD) TD is generally defined as the passage of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any
Slide 4: © Immuren
© Immuren
Slide 5: References
References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff
Slide 6: © Immuren
© Immuren
Slide 7: November 2024 - Steven Lydeamore, CEO
1 1 AGM PRESENTATION 18 NOVEMBER, 2024 NASDAQ: IMRN ASX: IMC Steven Lydeamore - CEO
Slide 8: Forward-looking statements
2 2 Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended
Slide 9: Executive Summary
3 3 EXECUTIVE SUMMARY Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases Company Overview • Platform Technology: capable of producing highly specific ora
Slide 10: Naval Medical Research Command Trial
4 4 NAVAL MEDICAL RESEARCH COMMAND TRIAL NMRC experimental campylobacter/ETEC vaccine o The trial was funded by the Naval Medical Research Command (NMRC). Immuron’s produced a hyperimmune bovine colostrum (HBC) trial product using the NMRC vaccine which was tested in a controlled human infection mod
Slide 11: Strong Pipeline with Near Term Milestones
5 5 STRONG PIPELINE WITH NEAR TERM MILESTONES 5 5 Market Phase III Phase II Phase I Partner Compound or brand name Travelan® Market Phase III Phase II Phase I Indication Compound or brand name Traveler’s Diarrhea ETEC challenge IMM - 124E Travelan® Clostridioides difficile Infection & Recurrence IMM
Slide 12: Travelan Progresses Towards Phase 3
6 6 TRAVELAN® PROGRESSES TOWARDS PHASE 3 Travelan® (IMM - 124E) Phase 2 o Travelan® IND Approval – December 2022 o Study Initiation – May 2023 o First cohort recruitment completed – July 2023 o Presentations at Military Health System Research Symposium – August 2023 o Second cohort recruitment compl
Slide 13: IMM-529 Progression to Phase 2
7 7 IMM - 529 PROGRESSION TO PHASE 2 IMM - 529 Clinical Development for Treatment of C. difficile Infections o Opportunity Assessment completed by o C. difficile infection (CDI) affects just over ~400,000 people in the US annually o S izable number of patients who experience at least one recurrence
Slide 14: Immuron's Clinical Programs - Opportunity Assessment
8 8 IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT Corporate › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonst
Slide 15: Continued Strong Sales Growth
9 9 CONTINUED STRONG SALES GROWTH o Global sales increased by 172% in the 2024 fiscal year to a record A$4.90 million compared to A$1.80 million in FY23 o Record monthly sales in October 2024 of $1.49 million o Australia o FY24: a record A$3.75 million; up 223% o Q1, FY25: A$1.01 million o October 2
Slide 16: Expansion of Travelan Distribution
10 10 EXPANSION OF TRAVELAN® DISTRIBUTION
Slide 17: Consumer Marketing Activity Driving Travelan Sales Growth
11 11 CONSUMER MARKETING ACTIVITY DRIVING TRAVELAN® SALES GROWTH We continue to drive awareness, consideration and engagement o Ranging across major retailers (Australia, Canada) o In - store positioning and promotion o Retailer catalogues o Search and social media marketing o Social competitions o
Slide 18: Contact Information
12 12 EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +613 8892 4854 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:
Slide 19: Scientific references
13 Scientific references Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research Sy